Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

Similar documents
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

Polycystic Ovary Syndrome (PCOS):

Polycystic Ovary Syndrome

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

Polycystic Ovarian Syndrome (PCOS) LOGO

JMSCR Vol 05 Issue 05 Page May 2017

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

Prevalence and symptomatology of polycystic ovarian syndrome in Indian women: is there a rising incidence?

SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY

Clinical Profile Polycystic Ovarian Syndrome Cases

Polycystic Ovary Syndrome

Overview of Reproductive Endocrinology

PCOS and Obesity DUB is better treated by OCPs

Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai

New PCOS guidelines: What s relevant to general practice

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Research Article. Ramanand SJ 1, Raparti GT 2 *, Halasawadekar NR 1, Ramanand JB 3, Kumbhar AV 1, Shah RD 1

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

PCOS. Reproductive Gynaecology and Infertility. Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al

Doppler flow velocities of uterine and ovarian arteries & hormonal patterns in patients with Polycystic Ovary Syndrome (PCOS)

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

A study on the clinical, biochemical and hormonal profile of polycystic ovary syndrome patients attending tertiary care hospital

Amenorrhoea: polycystic ovary syndrome

16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA

Department of Obstetrics and Gynecology, Benha Faculty of Medicine, Benha University, Egypt

JMSCR Vol 05 Issue 04 Page April 2017

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

Abnormal Uterine Bleeding Case Studies

X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.

Case. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?

UNDERSTANDING PCOS AND ITS DIAGNOSIS

Clinical Study and Outcome of Polycystic Ovarian Syndrome

Antim ullerian hormone and polycystic ovary syndrome

INFERTILITY CAUSES. Basic evaluation of the female

Nature and Science 2017;15(8)


WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

Uterus & Ovary 2015; 2: e904. doi: /uo.904; 2015 by Ahmed M Maged, et al.

THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Serum Vascular Endothelial Growth Factor in Polycystic Ovary Syndrome and its Relation to Ovarian Drilling

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University

New York Science Journal 2017;10(8)

Three-dimensional ultrasound features of the polycystic ovary and the effect of different phenotypic expressions on these parameters

POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015

Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study

Clinical evaluation of hirsutism in South India

Clinical study of polycystic ovarian syndrome (PCOS) in tertiary care centre

The Impact of Insulin Resistance on Long-Term Health in PCOS

PCOS guidelines: What s relevant to general practice

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome

Clinical correlation with biochemical status in polycystic ovarian syndrome

Investigation of adrenal functions in patients with idiopathic hyperandrogenemia

International Journal of Current Medical And Applied Sciences.vol.1. Issue: 1, 2013, PP 11-15

ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME

Infertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page

The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS

Comparative Evaluation of Diagnostic Efficacy of Serum. Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome

Estimation of serum 25 hydroxy vitamin D level and its correlation with metabolic and endocrine dysregulation in women with PCOS

13 th Annual Women s Health Day PCOS. Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH

A study of N-acetyl cysteine, metformin and vitamin D3 with calcium on clinical and metabolic profile in PCOS

Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population

3. Metformin therapy for PCOS

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

Prof.Dr. Nabil Lymon Head of Internal Medicine Department

From the editors desk

Salivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia

Anovulatory Infertility: A Prospective Study

Syndrome in Clinical Practice

The Pharmacology of PCOS

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

POLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Introduction. Review article

Polycystic ovary syndrome

Selection criteria of normal controls to predict reliable cut-off values of various endocrine parameters in infertility

Senior resident 5 lll rd year P.G. student

Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women

Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome

THE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE

Neil Goodman, MD, FACE

Reproductive Health and Pituitary Disease

Page 196. Corresponding Author: Swati Garg, Volume 3 Issue - 4, Page No

Antithyroid Peroxidase Antibodies in Women with Polycystic Ovary Syndrome

Transcription:

https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using Three-Dimensional Power Doppler Ultrasonography Nitasha Garg 1 Harkiran Kaur Khaira 1 Manjot Kaur 2 Smita Sinha 1 Received: 20 January 2017 / Accepted: 5 December 2017 / Published online: 21 December 2017 Ó Federation of Obstetric & Gynecological Societies of India 2017 About the Author Dr. Nitasha Garg has obtained her MBBS training from Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune. She is presently pursuing her postgraduate training in the Department of Obstetrics and Gynecology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab. She has keen interest in high-risk obstetrics and infertility. Dr. Nitasha Garg is a postgraduate scholar in the Department of Obstetrics and Gynecology, Adesh Institute of Medical Sciences and Research at Bathinda, Punjab; Dr. Harkiran Kaur Khaira, M.D., FICMCH, is a professor in the Department of Obstetrics and Gynecology, Adesh Institute of Medical Sciences and Research at Bathinda, Punjab, India; Dr. Manjot Kaur, M.D., is a Professor in the Department of Radiodiagnosis, Adesh Institute of Medical Sciences and Research at Bathinda, Punjab, India; Dr. Smita Sinha, M.S., is an associate professor in the Department of Obstetrics and Gynecology, Adesh Institute of Medical Sciences and Research at Bathinda, Punjab, India. & Nitasha Garg nitasha2812@gmail.com 1 2 Department of Obstetrics and Gynecology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India Department of Radiodiagnosis, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India Abstract Purpose of the Study To compare the quantitative assessment of blood flow and vascularization of ovaries in polycystic ovary syndrome patients and normal women using three-dimensional power Doppler ultrasonography. Methods This cross-sectional quantitative study was conducted on women of reproductive age group (15 45 years) attending Gynaecology OPD AIMSR, Bathinda, Punjab. Thirty women were enrolled in polycystic ovarian syndrome (PCOS) group and 30 healthy women in control group. Women were categorized as polycystic ovary syndrome according to Rotterdam s criteria. The women with PCOS underwent transvaginal USG Doppler on day 6 of the cycle using 3D power Doppler USG equipment (GE

A Comparative Study on Quantitative Assessment of Voluson E8), and vascularization index (VI), flow index (FI) and vascularization flow index (VFI) were measured. Results The mean values of VI, FI and VFI measured by power Doppler ultrasonography were significantly increased (P value = 0.000) in women with PCOS when compared with healthy women. Conclusion This study suggests that blood flow and vascularization measured by 3D power Doppler ultrasonography in ovaries of polycystic ovary syndrome patients were significantly more than the ovaries of normal women. Keywords Polycystic ovary syndrome Three-dimensional power Doppler ultrasonography Vascularization index (VI) Flow index (FI) Vascularization flow index (VFI) Introduction Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders affecting female fertility, although its etiology remains unknown. The criteria for diagnosis and definition of polycystic ovary disease are as heterogeneous as the pathology itself. So, it is the time for the development of a more objective method for the definition of PCOS. The blood flow and the vascular pattern of an organ are directly related to its morphology and function. Ultrasonography may be used as a valuable tool to detect the same. With the recent advent of 3D power Doppler ultrasonography, it is now possible to quantify blood flow information of ovaries in the form of vascularization index (VI) representing vessels in tissues showing the flow signals, flow index (FI) representing intensity of flow and vascularization flow index (VFI) representing combination of VI and FI. The aim of the present study was to evaluate the characteristics of polycystic ovaries compared to normal ovaries using 3D power Doppler ultrasonography with the purpose that this information might provide an additional parameter for the ultrasound diagnosis of the PCOS, hence may prove a new objective method for the diagnosis of PCOS. Aim and Objective Aim To compare the quantitative assessment of blood flow and vascularization of ovaries in polycystic ovary syndrome patients and normal women using three-dimensional power Doppler ultrasonography. Materials and Methods This cross-sectional study was carried out in the Department of Obstetrics and Gynaecology and Department of Radiodiagnosis, AIMSR, Bathinda, which is a tertiary care teaching hospital in the state of Punjab. The study was carried out from July 2015 to Oct 2016 after obtaining clearance from the scientific and ethical committee of the hospital. A written informed consent was taken from the participants before enrollment. Inclusion Criteria Cases were included in the study based on Rotterdam s criteria (Table 1). Exclusion Criteria 1. Women with history of use of oral contraceptives, corticosteroids, antipsychotic drugs or antidiabetic drugs in the last 3 months 2. Patients with other known causes of hyperandrogenism like Cushing syndrome, late onset adrenal hyperplasia, androgen-secreting tumor or hyperprolactinemia. 3. Patients with untreated hypothyroidism, renal, hepatic, cardiac or pulmonary disease. 4. Smokers or alcoholics. 5. All pregnant women. Formula for quantitative observational study was used for sample size calculation. Sample size turned out to be 29 patients in each group. We enrolled 30 patients in each group for the study. Methods A detailed history from all the subjects was taken and clinical examination performed. On day 2 of the menstrual cycle, fasting blood samples were collected from all the subjects in plain vial for estimation of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, testosterone, dehydroepiandrosterone sulfate (DHEAS), prolactin, thyroid-stimulating hormone (TSH), insulin and blood glucose (FBS). Hormonal levels were measured by Table 1 Rotterdam s criteria [1] Two of the three criteria below and exclusion of other etiologies (e.g., congenital hyperplasia, androgenic tumors, cushing syndrome) 1. Oligo and/or anovulation 2. Clinical and/or biochemical signs of hyperandrogenism 3. Polycystic ovaries 137

Garg et al. The Journal of Obstetrics and Gynecology of India (March April 2018) 68(2):136 141 Fig. 1 Power Doppler ultrasonography histogram Tosoh AIA 360 automatic hormone analyzer (Immunoflorescence), and blood glucose was measured using automated analyzer A15-Biosystems (Spectrophotometry). Normal reference value taken for LH was 1.7 13.3 miu/ml, FSH was 4.5 11.0 miu/ml, S. estradiol was 40.7 220.4 pg/ml, S. testosterone was 9.0 56.0 ng/dl, DHEAS was 65 524 lg/dl, fasting insulin was 1.1 17.0 lg/ml, fasting glucose was 70 100 mg/dl, HOMA IR was B 2, TSH was 0.39 6.2 liu/ml and S. prolactin was 2.1 47.6 ng/ml. The Rotterdam s consensus defined the polycystic ovary as having 12 or more follicles, measuring between 2 and 9 mm, and/or an ovarian volume (OV) [ 10 cm 3. Only one ovary meeting these criteria is sufficient to establish the presence of polycystic ovaries [1]. Transvaginal 3D power Doppler ultrasonography (GE Voluson E8) was performed on day 6 of the cycle to measure total ovarian volume, follicular size and number, endometrial thickness, vascularization index (VI), flow index (FI) and vascularization flow index (VFI) using Virtual Organ Computer-aided Analysis (VOCAL) imaging program (Fig. 1). Table 2 Clinical characteristics of cases and control groups Variable Group 1 Group 2 Significance Age Mean ± SD 26.37 ± 3.855 23.83 ± 4.949 NS Menstrual history Regular 1 30 S Irregular 29 0 S H/o weight gain 4 4 NS H/o stress 16 0 S Height Mean ± SD 156.23 ± 3.15 157.53 ± 5.69 NS Weight Mean ± SD 65.37 ± 3.47 55.2 ± 7.84 S Body mass index Mean ± SD 26.8 ± 1.53 22.2 ± 2.6 S Waist circumference Mean ± SD 88.08 ± 6.7 81.3 ± 4.46 S Hip circumference Mean ± SD 89.73 ± 8.75 85.47 ± 5.58 NS Waist/hip ratio Mean ± SD 0.99 ± 0.1 0.95 ± 0.5 NS Table 3 Comparison of biochemical characteristics in cases and controls groups LH Mean ± SD 15.87 ± 7.5 5.75 ± 1.7 0.000 FSH Mean ± SD 8.59 ± 2.8 7.79 ± 1.2 0.162 ESTRADIOL Mean ± SD 37.73 ± 4.4 29.22 ± 4.4 0.000 TESTOSTERONE Mean ± SD 44.52 ± 12.18 37.78 ± 11.06 0.029 DHEAS Mean ± SD 197.66 ± 53.75 157.36 ± 46.35 0.003 FASTING INSULIN Mean ± SD 15.99 ± 4.2 11.19 ± 2.72 0.000 FBS Mean ± SD 89.03 ± 4.98 77.13 ± 6.47 0.000 HOMA IR Mean ± SD 3.53 ± 1.01 2.14 ± 0.59 0.000 TSH Mean ± SD 2.38 ± 0.84 2.34 ± 0.95 0.861 PROLACTIN Mean ± SD 11.79 ± 3.40 11.40 ± 3.51 0.671 HOMA IR fasting glucose (mg/dl) 9 fasting insulin (lu/ml)/405 [2] 138

A Comparative Study on Quantitative Assessment of Table 4 Comparison of two-dimensional ultrasonographic findings of cases and controls groups Volume of left ovary Mean ± SD 12.27 ± 4.1 6.90 ± 1.4 0.000 Volume of right ovary Mean ± SD 12.238 ± 3.8 7.649 ± 1.7 0.000 Number of follicles (left ovary) Mean ± SD 12.40 ± 2.9 5.33 ± 1.2 0.000 Number of follicles (right ovary) Mean ± SD 12.97 ± 2.3 4.93 ± 1.1 0.000 Endometrial thickness Mean ± SD 4.890 ± 1.4 4.947 ± 0.9 0.851 Table 5 Comparison of power Doppler indices in left and right ovaries of cases and controls groups Difference VI (left right) Mean ± SD 1.51 ± 5.79 5.2 ± 0.86 0.361 Difference FI (left right) Mean ± SD 1.47 ± 5.99 2.88 ± 4.91 0.321 Difference VFI (left right) Mean ± SD 0.55 ± 2.12 0.45 ± 0.81 0.816 Table 6 Comparison of average of power Doppler indices of bilateral ovaries in cases and control groups Average VI Mean ± SD 7.26 ± 4.63 0.88 ± 0.51 0.000 Average FI Mean ± SD 28.23 ± 4.69 16.61 ± 3.12 0.000 Average VFI Mean ± SD 2.15 ± 1.48 0.16 ± 0.40 0.000 Table 8 Comparison of power Doppler indices in both the groups in subjects having LH/FSH [ 1 VI Mean ± SD 6.19 ± 4.82 0.37 ± 0.39 0.001 FI Mean ± SD 26.18 ± 5.56 15.17 ± 4.44 0.008 VFI Mean ± SD 1.67 ± 1.59 0.05 ± 0.05 0.001 For estimation level of association, unpaired t test was used. P value \ 0.05 was taken as significant. Microsoft Excel 2013 was used to analyze the data. Results A total of 30 cases (PCOS women) Group 1 and 30 controls (normal women) Group 2 were taken. Women in the two groups were compared with respect to clinical characteristics, as shown in Table 2. Menstrual history, history of stress, height, weight, BMI and waist circumference had statistically significant difference in the two groups. However, age, history of weight gain, height, hip circumference and waist to hip ratio were not statistically significant in the two groups. Clinical signs of hyperandrogenism like acne were present only in PCOS group in 46.7% cases; alopecia and acanthosis nigricans were present only in one PCOS women, while hirsutism was present in 20% of PCOS women. Table 3 shows comparison of biochemical characteristics in cases and controls. LH, FSH, estradiol, testosterone, DHEAS, fasting insulin, fasting blood sugar, TSH and prolactin were measured on day 2 of the menstrual cycle. The mean of LH, estradiol, DHEAS, fasting insulin, fasting blood sugar and homeostatic model assessment-insulin resistance (HOMA IR) was found to be significantly higher in PCOS group than the control group, while the difference of FSH, testosterone, TSH and prolactin was not statistically significant. Difference in volume of ovaries and number of follicles between the two groups was found to be statistically Table 7 Comparison of power Doppler indices in cases and control group on the basis of age-wise distribution Age (years) 16 25 26 35 16 25 26 35 VI Mean ± SD 6.76 ± 4.56 6.33 ± 4.97 0.53 ± 0.53 0.81 ± 0.86 0.001 FI Mean ± SD 27.13 ± 6.81 27.46 ± 5.83 15.68 ± 4.10 14.15 ± 3.53 0.001 VFI Mean ± SD 1.86 ± 1.28 1.86 ± 1.87 0.09 ± 0.09 0.13 ± 0.15 0.001 139

Garg et al. The Journal of Obstetrics and Gynecology of India (March April 2018) 68(2):136 141 Table 9 Comparison of power Doppler indices in both the groups in subjects having HOMA IR [ 2 significant. Volume of ovaries was higher in PCOS women. Also, number of follicles were more in PCOS women than normal women (Table 4). The difference between left and right ovary of power Doppler indices was not statistically significant (Table 5). So, average of bilateral ovaries was measured. There was statistically significant difference of VI, FI and VFI between normal and PCOS women. Values were higher in PCOS group (Table 6). To consider age-related changes in ovarian vascularity, the subjects were classified in two groups, 16 25 and 26 35 years and power Doppler indices were compared between the two groups. VI, FI and VFI of PCOS women were higher than the normal women in both the age groups (Table 7). Comparison of LH/FSH ratio and insulin resistance using HOMA IR with the ovarian vascularity was also done. Patients having increased LH/FSH ratio had significantly higher values of VI, FI and VFI (Table 8). Also, insulin-resistant subjects had significantly raised VI, FI and VFI (Table 9). Discussion VI Mean ± SD 6.50 ± 4.74 0.63 ± 0.67 0.001 FI Mean ± SD 27.32 ± 6.13 15.27 ± 3.96 0.001 VFI Mean ± SD 1.86 ± 1.63 0.10 ± 0.11 0.001 The hypothesis in the present study was that 3D power Doppler ultrasonography provides the possibility of systemic analysis of volume, blood flow and vascularization of the whole ovary. In this study, we used VOCAL-imaging program to compare 30 controls and 30 PCOS patients according to Rotterdam s criteria. The ovary was examined during early follicular phase and not during the late follicular phase when developing follicle of[ 10 mm diameter is likely. In the present study, the ovary was examined on day 6 (early follicular phase). The results were in accordance with those recently presented by Al-Rab et al. [3], El Behery et al. [4] and Elmashad et al. [5]. They used similar 3D power Doppler ultrasonography to compare VI, FI and VFI between normal and PCOS group. They discovered that polycystic ovaries have increased stromal blood flow and vascularity like in the present study. But in the study by Lam et al. [6], Chinese women with PCOS had no significant differences in the 3D indices of ovarian vascularity and blood flow compared to the control group. Lam et al. recruited 40 Chinese women with PCOS from the assisted reproductive technology unit and the gynecology clinic as the study group and 40 subfertile Chinese women without PCOS who were undergoing intrauterine insemination treatment and/or ovulation induction for infertility due to male factors or to unexplained infertility as the control group. The reasons for this contradiction between Lam et al. and this study might be that different control groups were used in these two studies. We selected normal healthy volunteers with regular cycles and normal ovaries while Lam et al. chose subfertile women. Moreover, ovarian characteristics might be influenced by ethnicity also. Our results suggest that in general the blood flow in polycystic ovaries was more than the normal ovaries in early follicular phase. Three-dimensional power Doppler ultrasonography offers us a new tool to assess size of target organ, to quantify tissue blood perfusion, which may expand our knowledge concerning physiology of the organs. Although the implication of this finding in ovulation induction treatment is unknown, it may help to explain the excessive response often seen in women with PCOS when they are administered gonadotrophins [7]. The presence of an increased stromal Doppler signal in the PCOS group [8], compared with women with normal ovaries, supports the notion that PCOS is a primary disorder of the ovary. Conclusion The detection of an increased total ovarian Doppler signal by 3D power Doppler ultrasonography may be a possible new marker in the diagnosis of PCOS. Our results suggest that blood flow in ovaries of polycystic patients was more than in ovaries of normal women in early follicular phase. PCOS patients are more sensitive to the stimulation of gonadotrophins and are at higher risk of ovarian hyperstimulation syndrome. Increased ovarian blood flow in PCOS patient may lead to a greater dose of gonadotrophins to the granulosa cells of the developing follicles. Therefore, the assessment of the ovarian blood flow should be incorporated in the management of PCOS women undergoing ovulation induction or ovarian stimulation in order to reduce the associated risk of ovarian hyperstimulation syndrome. We believe that 3D power Doppler ultrasound may provide substantial assistance to the management of PCOS 140

A Comparative Study on Quantitative Assessment of and is worthy of further research. However, further studies with larger sample size are definitely needed in this area. Compliance with Ethical Standards Conflict of Interest The authors declared that there was no conflict of interest. Ethical Approval Research protocol was approved by the institutional ethics committee. Informed Consent Informed consent was obtained from all subjects for being included in the study. References 1. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565 92. 2. Gianchandani RY, Saberi S, Patil P, et al. Prevalence and determinants of glycemic abnormalities in cardiac surgery patients without a history of diabetes: a prospective study. Front Endocrinol. 2015;6:125. 3. Al-Rab MT, Mohammed AB, Mo men MH, et al. Three-dimensional power Doppler indices of ovarian stromal blood flow and serum vascular endothelial growth factor after laparoscopic ovarian drilling in women with polycystic ovary syndrome. Middle East Fertil Soc J. 2015;20(3):138 43. 4. El Behery MM, Diab AE, Mowafy H, et al. Effect of laparoscopic ovarian drilling on vascular endothelial growth factor and ovarian stromal blood flow using 3-dimensional power Doppler. Int J Gynecol Obstet. 2011;112(2):119 21. 5. Elmashad AI. Impact of laparoscopic ovarian drilling on anti- Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory polycystic ovary syndrome. Fertil Steril. 2011;95(7):2342 6. 6. Lam P, Raine-Fenning N, Cheung L, et al. Three-dimensional ultrasound features of the polycystic ovary in Chinese women. Ultrasound Obstet Gynecol. 2009;34(2):196 200. 7. Dumont A, Robin G, Catteau-Jonard S, et al. Role of Anti- Müllerian Hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol. 2015;13(1):1. 8. Senaldi L, Gopi RP, Milla S, et al. Is ultrasound useful in the diagnosis of adolescents with polycystic ovary syndrome? J Pediatr Endocrinol Metab. 2015;28(5 6):605 12. 141